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Abstract
1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23)
and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in
basic osteoporosis treatment. We wanted to know if 1,25D3 is able to modulate aging processes on a cellular level in human
mesenchymal stem cells (hMSC). Effects of 100 nM 1,25D3 on hMSC were analyzed by cell proliferation and apoptosis assay,
b-galactosidase staining, VDR and surface marker immunocytochemistry, RT-PCR of 1,25D3-responsive, quiescence- and
replicative senescence-associated genes. 1,25D3 treatment significantly inhibited hMSC proliferation and apoptosis after
72 h and delayed the development of replicative senescence in long-term cultures according to b-galactosidase staining
and P16 expression. Cell morphology changed from a fibroblast like appearance to broad and rounded shapes. Long term
treatment did not induce lineage commitment in terms of osteogenic pathways but maintained their clonogenic capacity,
their surface marker characteristics (expression of CD73, CD90, CD105) and their multipotency to develop towards the
chondrogenic, adipogenic and osteogenic pathways. In conclusion, 1,25D3 delays replicative senescence in primary hMSC
while the pro-aging effects seen in mouse models might mainly be due to elevated systemic phosphate levels, which
propagate organismal aging.
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Introduction
The biologically active metabolite of vitamin D, 1,25-dihydrox-
yvitamin D3 (1,25D3) is synthesized from precursors by sequential
hydroxylations in the liver (25-hydroxylase) and kidney (1a-
hydroxylase) [1–2]. 1,25D3 is involved in calcium and phosphate
homeostasis through its effects on target organs such as intestine,
kidney, parathyroid gland and bone [3–4]. There is also some
evidence for a close association between hypervitaminosis D and
accelerated aging in mice models [5]. Combined binding of the
phosphatonin FGF23 and the longevity-associated gene product
Klotho to the FGF receptor type 1 exerts FGF23 specific signaling
[6]. Both, Fgf23-deficient (Fgf23
2/2) and klotho (kl
2/2) deficient
mice, show a similar phenotype displaying growth retardation,
growth plate abnormalities, highly elevated serum phosphate and
serum 1,25D3 levels, infertility, arteriosclerosis, premature aging
and a shortened lifespan [7–8]. Ablation of the vitamin D
activation pathway by additional knockout of the 1a-hydroxylase
gene reverses anomalies in Fgf23
2/2 mice [9] and genetic
inactivation of 1a-hydroxylase gene in kl
2/2/1a(OH)ase
2/2 mice
reversed or abated the typical features observed in kl
2/2 mice
[10]. Furthermore it was demonstrated that in Fgf23
2/2 mice with
a non-functioning vitamin D receptor (VDR) the bone, mineral
and glucose homeostasis could be rescued [11]. Therefore,
interventions affecting the vitamin D responsive signal transduc-
tion seem to be closely linked to aging phenomena [5]. In contrast
to these results, which linked VDR-dependent signaling to
premature aging, it has been recently shown that VDR deficient
mice develop premature aging phenomena, indicating that VDR-
signaling might have anti-aging effects [12].
Mammalian aging is a complex biological process that can be
defined as a progressive deterioration of physiological functions,
as a decline of the functionality and regenerative capacity of all
tissues and organs. It is accompanied by age-related diseases like
arteriosclerosis, dementia, and osteoporosis [13]. Monogenetic
mouse models and diseases in humans indicate that besides other
mechanisms DNA and protein damage accumulation is
associated with premature aging. Oxidative stress caused by
reactive oxygen species (ROS) induces damage of the genome
and proteome and promotes aging [14–15]. An imbalance
between ROS production and detoxification leads to an increase
of the ROS induced damage. The neutralization of ROS by a
series of antioxidative enzymes and small molecules, e. g.
superoxide dismutases or glutathione peroxidases, is an impor-
tant segment of detoxification which also modulates the aging
process [16].
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are multipotent and can give rise to mesenchymal tissues like bone,
cartilage, and fat. They are a principal source of regeneration and
healing and may be valuable tools for cell based regenerative
therapies [17–18].
The aim of the present study was to characterize the effect of
1,25D3 on aging processes in hMSC. This was investigated in a
series of experiments including e.g. RT-PCR analysis of
quiescence- and senescence-associated genes, proliferation pace
and ROS accumulation. Our hypothesis was that 1,25D3 is not a
pro-aging compound at the cellular level and after having
performed pilot studies we extended the hypothesis in that it
might even delay cellular senescence.
Results
VDR immunocytochemistry and expression of 1,25D3
responsive genes in hMSC
The effect of 1,25D3 on mRNA expression of responsive genes
in hMSC was analyzed after stimulating cells from three donors
for 24 h. To validate the method and to analyze regulation in
hMSC we first amplified genes, known to be affected by 1,25D3
[19]. RT-PCR analysis resulted in an enhanced expression of 24-
hydroxylase (CYP24A1), osteocalcin (OC) and osteopontin (OPN)i n
all three donors compared to unstimulated control cells (Fig. 1A/
B). In summary, 1,25D3 modulates the expression of 1,25D3
responsive genes in hMSC.
Incubation of hMSC for 24 h with the VDR ligand 1,25D3
leads to a translocation of the liganded receptor into the nucleus,
which was demonstrated by immunostaining with an antibody
against human VDR (Fig. 1C). The intensive staining of a region
overlapping with the nucleus, showed by DAPI staining,
confirmed the nuclear translocation of liganded receptor in
hMSC.
Immunophenotype of hMSC treated with or without
1,25D3 at P1 and P3
The immunophenotype of hMSC was screened by surface
antigen characterization using flow cytometry analysis (Fig. S1).
To delineate possible phenotypic changes over time we analyzed
P1 and P3 of 1,25D3 treated hMSC compared to untreated
hMSC. Flow cytometry was not able to distinguish any differences
between 1,25D3 stimulated hMSC and control hMSC at P1 and
P3. Both, 1,25D3 treated hMSC and untreated cells, were
negative for the hematopoietic markers CD34, CD45 and HLA-
DR (Fig. S1, right panels), and positive for the mesenchymal
markers CD73, CD90 and CD105 (Fig. S1, left panels). Fig. S1
Figure 1. 1,25D3 response in hMSC. A/B 1,25D3 stimulation of hMSC resulted in a strong increase of CYP24A1 expression in all three donors.
Control cells showed no CYP24A1 expression, therefore densitometric quantification was not possible (A). The induction of OC expression is
considerable and significant (**, p,0.01, student’s t-test), the OPN expression is less intense. Densitometric quantification of OC and OPN expression
was performed. For each donor the Fold Change was calculated by comparing the expression of 1,25D3 treated cells with control cells. The results
were obtained from three independent donors and are shown as mean+SEM (B). C Immunostaining of VDR in hMSC after stimulation with 1,25D3 for
24 h. Stimulated cells show an increased localization of VDR in the nucleus, whereas the staining of the control cells is more diffuse (upper panel).
Counterstaining with DAPI displays the localization of the nucleus (lower panel). One representative experiment is shown. Experiments were
performed three times.
doi:10.1371/journal.pone.0029959.g001
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CD90 and CD105 positivity. The expression of CD73, CD90 and
CD105 of 1,25D3 treated hMSC and untreated cells was between
88.9% and 98.7%.
Clonogenic capacity of 1,25D3 treated and untreated
hMSC
1,25D3 stimulated and control hMSC were assayed for colony
forming unit (CFU) frequency at P1 and P3, using cells from three
donors (P3) and five independent donors (P1), respectively. No
difference was observed between the two groups in terms of colony
numbers at P1 and P3 (Fig. S2). The CFU frequency was highly
donor-dependent and ranged from 318–1352 CFUs per 800
seeded hMSC at P1 and from 412–709 CFUs per 800 seeded cells
at P3. Neither P1 nor P3 showed a significant correlation between
1,25D3 treatment and the number of CFUs. However, a
nonsignificant decrease in CFUs could be observed in sets of
cultures established at P3 in comparison to P1.
Short term effects of 1,25D3 on proliferation and
apoptosis in hMSC
Stimulation of hMSC from three donors for 24, 48 and 72 h
with 1,25D3 revealed similar effects on proliferation and
apoptosis. 1,25D3 treatment of hMSC leads to a significant
inhibition of cell proliferation after 48 h (17% reduction; **,
p,0.01) and 72 h (27% reduction; ***, p,0.001) (Fig. 2A). Only a
marginal inhibition of cell proliferation was noted after 24 h
treatment. The apoptosis of hMSC was inhibited by 1,25D3
treatment after 48 h (12% reduction) and 72 h (23%; *, p,0.05),
respectively. After 24 h only minor effects on apoptosis could be
observed (Fig. 2B).
Growth rate of hMSC permanently treated with 1,25D3
The proliferation capacities (cumulative population doublings,
CPDs) of hMSC grown under permanent 1,25D3 treatment
showed lower CPDs (gray bar) versus control cells (black bar)
(Fig. 2C). The proliferation rate of control hMSC was somewhat
Figure 2. 1,25D3 effects on proliferation, apoptosis and cumulative population doublings. A/B Measurement of proliferation capacity
and apoptosis induction of hMSC from three different donors after stimulation with 1,25D3 for 24, 48 and 72 h. The proliferation rate was decreased
time-dependently after 1,25D3 treatment (gray bars) compared to control cells (black bars), with significant effects after 48 h and 72 h (A). 1,25D3
stimulation showed the strongest reduction of apoptosis rates after 72 h 1,25D3 treatment (gray bars) compared to control cells (black bars, B). The
results are shown as mean+SEM of three independent experiments, each normalized to its control and performed in triplicates. Cells from three
different donors were used. (*, p,0.05; **, p,0.01;***, p,0.001, student’s t-test). C The growth rates of cells were determined by population
doublings at each subcultivation. Cumulative population doubling (CPD) was first determined for P2. Population doublings were observed for up to
six cell passages. Persistent 1,25D3 supplementation resulted in a reduction of population doublings (gray bar), but the difference was not statistically
significant. Independent experiments were performed using hMSC from several human donors. Control: P1, P2, n=6; P3, P4, n=5; P5, n=3; P6, n=2.
1,25D3: P1, P2, n=6; P3, P4, n=4; P5, P6, n=1. D A representative example of CPDs of cells from one donor. 1,25D3 cultured cells exhibited lower
CPDs compared to control hMSC (**, p,0.01, student’s t-test). E The time required to reach subconfluence was determined. 1,25D3 treated cells (gray
bars) needed more days until they reached subconfluence compared to control hMSC (black bars) (**, p,0.01, student’s t-test). Independent
experiments were performed using hMSC from several human donors. Control: P1, P2, P3, P4, n=6; P5, n=5; P6, n=3. 1,25D3: P1, P2, P3, n=6; P4,
n=5; P5, n=4; P6, n=1.
doi:10.1371/journal.pone.0029959.g002
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cells. The CPDs of hMSC from several different donors (as
indicated in the legend) were analyzed for up to six passages
(Fig. 2C). Figure 2D shows growth curves and their respective
CPDs for one donor. 1,25D3 treated hMSC displayed significantly
lower CPDs compared to control cells (**, p,0.01). Although
there was a donor-related variability of the proliferation rate,
1,25D3 stimulation caused an obvious growth retardation and
1,25D3 stimulated cells needed significantly more days until they
reached subconfluence (**, p,0.01) (Fig. 2E). The results are
shown as mean from several donors (see figure legend for more
information) and were consistent in all investigated donors.
Morphological characteristics of 1,25D3 cultured hMSC
1,25D3 treatment induced obvious morphological changes in
hMSC. Cells lost their typical fibroblast-like features, enlarged
their original cell volume and developed broadened and extended
shapes compared to untreated hMSC. No signs of spontaneous
differentiation, e.g. towards the development of lipid droplets or
mineralization induction could be observed (Fig. 3A).
Retransformation of 1,25D3 stimulated hMSC
These 1,25D3 induced morphological changes in hMSC are
partially reversible. After 1,25D3 treatment of hMSC over three
passages cells wereputback to normal medium (retransformed cells;
r.c.). After two weeks the morphological changes were partially
rescued (Fig. S3A). Some cells retained their 1,25D3 induced
enlarged phenotype, some cells got their typical fibroblast-like
features back. The cell number of control cells was nonsignificantly
higher (average of three donors: cell number=1.6610
5) compared
to the cell number of 1,25D3 treated cells (average of three donors:
cell number=0.8610
5) at the same passages (Fig. S3B/C). The
results are shown for three donors and the observed phenomena
were consistent over all analyzed hMSC donors.
Senescence-associated ß-galactosidase in 1,25D3
stimulated hMSC
The impact of 1,25D3 on cellular senescence was determined by
senescence-associated ß-galactosidase staining in stimulated and
unstimulated hMSC. Three different donors were cultivated with
and without 1,25D3 for up to three passages. In stimulated hMSC
(gray bar) a significant reduction of ß-galactosidase staining was
observed compared to unstimulated cells (black bar) (p,0.001)
(Fig. 3B). Furthermore we were able to follow up one donor for
nine passages and compared 1,25D3 treated cells to control cells of
P9. The significant effect, which was obvious at P3, was even more
impressive in this late passage. 40 percent reduction of senescent
hMSC could be counted (p,0.01) (data not shown).
ROS accumulation in 1,25D3 treated hMSC
The accumulation of ROS in 1,25D3 supplemented cells
compared to untreated hMSC after P1 and P3 was measured by
flow cytometry. As shown in Fig. S5A, a slight and nonsignificant
reduction of oxidative stress induction after treating hMSC for one
passage with 1,25D3 was observed. As depicted in Fig. S5B,
1,25D3 treatment of hMSC for a period of three passages led to a
significant increase in ROS formation (*, p,0.05).
Effects of 1,25D3 treatment on the trilineage
differentiation capacity of hMSC
The maintenance of the multilineage capacity of 1,25D3 treated
hMSC could be determined by subsequent chondrogenic,
adipogenic and osteogenic differentiation in comparison to
untreated controls. The induction of chondrogenesis, determined
by Alcian blue staining of proteoglycans (Fig. 4A, upper panel),
was quantified on digital images taken from chondrogenic pellets.
1,25D3 pretreatment increased the chondrogenic capacity of
hMSC compared to cells grown without 1,25D3 supplementation,
Figure 3. Morphological characteristics of 1,25D3 cultured hMSC and ß-galactosidase quantification. A Morphology of hMSC in P1
(upper row) and P3 (lower row) treated with 1,25D3 over three passages compared to control cells. 1,25D3 incubated hMSC lost their typical
fibroblast-like features and showed a broadened and extended cellular morphology. Scale bar=50 mm. B The induction of ß-galactosidase was
significantly reduced in 1,25D3 cultured cells compared to control hMSC. Cells from three different donors were used and were cultured up to three
passages. The results are shown as mean+SEM of three independent experiments, each normalized to its control. Each time five pictures of ß-
galactosidase staining were analyzed using the AutMess tool of AxioVision Rel. 4.6 software. (***, p,0.001, student’s t-test).
doi:10.1371/journal.pone.0029959.g003
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the donors was observed. Two donors displayed almost the same
chondrogenic induction between untreated differentiated cells and
1,25D3 pretreated hMSC, whereas one donor showed a strong
enhanced induction of chondrogenesis after 1,25D3 pretreatment.
We also determined the adipogenic capacity of 1,25D3
pretreated cells versus untreated control hMSC. After adipogenic
induction, oil droplet formation was found to a lesser extent in
control hMSC than in 1,25D3 pretreated cells (Fig. 4A, middle
panel). This difference was not statistically significant (Fig. 4B).
After two weeks under osteogenic conditions, 1,25D3 pretreated
hMSC showed a slightly enhanced ALP staining compared to
untreated cells (Fig. S4A, upper panel and B). This effect was
reversed after four weeks of osteogenic culturing (Fig. S4A, lower
panel and B), where both 1,25D3 pretreated and untreated hMSC
displayed an almost equivalent amount of mineralization shown by
Alizarin Red O staining (Fig. 4A, lower panel and B).
Effects of 1,25D3 treatment on the expression of
quiescence markers
To investigate if 1,25D3 treatment over three passages had an
impact on cellular quiescence, we analyzed the expression level of
selected quiescence-associated genes. The gene expression of
forkhead box O1 (FOXO1a) displayed a fold change of 1.5,
forkhead box O3 (FOXO3a) was 1.2-fold up-regulated and
forkhead box O4 (FOXO4) was 1.7-fold up-regulated in 1,25D3
stimulated hMSC at P3 compared to control cells. Nanog
homeobox (NANOG) is slightly induced by 1,25D3 treatment and
revealed a fold change of 1.3. Thioredoxin interacting protein
(TxNIP) was induced in 1,25D3 treated cells and was 1.6 -fold
upregulated. Tumor protein p53 (TP53) showed a 1.9-fold
upregulation due to 1,25D3 treatment (Fig. 5A).
Effects of 1,25D3 treatment on the expression of
senescence markers
The gene expression of the senescence-associated genes cyclin-
dependent kinase inhibitor 2B (P15), cyclin-dependent kinase
inhibitor 2A (P16), cyclin-dependent kinase inhibitor 1A (P21)a n d
proteasome 26S subunit, non-ATPase, 9 (P27) in hMSC cultured
with or without 1,25D3 for four passages led to a significant 0.4-fold
(p,0.05) downregulation of P16 gene expression and to a
nonsignificant 1.6-fold upregulation of P15 expression compared
to control cells. 1,25D3 treatment had no effect on P27 expression
andP21expressionwasonlymarginallyinduced(foldchange=1.2).
Long-term stimulation of hMSC (P4) had also no significant effects
on mRNA expression of the senescence-associated pregnancy
specific beta-glycoproteins PSGs. We focused our analyses on
PSG1 and PSG5 and could demonstrate that the gene expression of
PSG1 was slightly 0.8-fold downregulated in 1,25D3 treated cells in
P4 while the expression of PSG5 was unchanged (Fig. 5B).
Figure 4. Trilineage differentiation capacity of 1,25D3 pretreated hMSC. A Chondrogenic, adipogenic and osteogenic differentiation of
hMSC after 1,25D3 pretreatment over three passages. Alcian Blue staining of chondrogenic differentiated hMSC (upper panel), Oil Red O staining for
intracellular lipid vesicles during adipogenic differentiation (middle panel) and Alizarin Red S staining of mineralized extracellular matrix after
osteogenic differentiation (lower panel) are shown (n.d.=not differentiated; C=differentiated control; +1,25D3=differentiated, cells pretreated for
three passages with 1,25D3). The figure is representative for three independent experiments. The bar represents 100 mm and 10 mm, respectively as
indicated. B Quantification of chondrogenic (black bar), adipogenic (dark gray bar) and osteogenic differentiation (light gray bar) after three passages
1,25D3 pretreatment in comparison to untreated cells. For each differentiation lineage the Fold Change was calculated by comparing the induction
of differentiation of 1,25D3 pretreated cells with control cells. The results are shown as means of three independent experiments+SEM using three
different preparations of hMSC. Each time 5 to 9 pictures of each differentiation experiment were analyzed using the AutMess tool of the software of
AxioVision Rel. 4.6.
doi:10.1371/journal.pone.0029959.g004
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Based on the knowledge of aging-promoting properties of
unbalanced systemic 1,25D3 excess in animal models we analyzed
cellular 1,25D3 effects on hMSC by cell proliferation and
apoptosis assay, b-galactosidase staining, VDR and surface marker
immunocytochemistry and RT-PCR of 1,25D3-responsive, quies-
cence- and replicative senescence-associated genes.
In order to validate the response of hMSC to 1,25D3 treatment,
we first showed that 1,25D3 short-term stimulation modulates the
responsive genes CYP24A1, OC and OPN in hMSC. Additionally,
nuclear translocation of the liganded VDR receptor could be
confirmed by immunostaining.
To characterize hMSC, which were stimulated with 1,25D3 for
three or more passages, we investigated surface marker analysis,
clonogenic capacity and cell morphology. The analysis of the
surface marker expression of 1,25D3 stimulated hMSC did not
change with respect to mesenchymal markers (CD73
+, CD90
+,
CD105
+) and hematopoetic markers (CD34
2, CD45
2, HLA-
DR
2) as analyzed by FACS in comparison to untreated cells.
Moreover there was no loss of clonogenic capacity in 1,25D3
treated hMSC. 1,25D3 treated hMSC lost their typical fibroblast-
Figure 5. Effects of 1,25D3 treatment on quiescence- and senescence-associated genes. A Expression of quiescence markers and
densitometric quantification of semiquantitative RT-PCR results of hMSC (P3) treated with or without 1,25D3. Cells from five different donors were
used. For each donor the Fold Change was calculated by comparing the expression of 1,25D3 treated cells with control cells. The results are shown as
mean+SEM. The gene expression levels of FOXO1a, FOXO3a, FOXO4, NANOG, TxNIP, TP53 were induced by 1,25D3 treatment over 3 passages.
(FOXO1a: forkhead box 1a, FOXO3a: forkhead box 3a, FOXO4: forkhead box 4, NANOG: Nanog homeobox, TxNIP: thioredoxin interacting protein,
TP53: tumor protein p53). B Expression of senescence markers and densitometric quantification of semiquantitative RT-PCR results of hMSC treated
with or without 1,25D3 over at least four passages. 1,25D3 treatment reduced P16 expression (p,0.05) and induced P15 expression in cells at P4
compared to control cells. P27 and P21 gene expression in P4 showed no (P27) or only very weak (P21) induction by 1,25D3 treatment. Densitometric
quantification of the semi-quantitative PCR results revealed downregulation of PSG1 and almost no change in the expression of PSG5 at P4 in 1,25D3
stimulated hMSC. The Relative Fold change represents the factor of different gene expression levels in 1,25D3 treated hMSC versus control cells.
Expression profile of senescence-associated genes was determined in P4. Cells from three different donors were used. For each donor the Fold
Change was calculated by comparing the expression of 1,25D3 treated cells with control cells. The results are shown as mean+SEM. (*, p,0.05,
student’s t-test).
doi:10.1371/journal.pone.0029959.g005
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broadened and extended shapes compared to untreated hMSC.
When 1,25D3 was withdrawn in long term cultures the
morphology only partially returned to the fibroblast like
appearance.
In short-term time response experiments, stimulation of hMSC
with 1,25D3 showed the strongest inhibitory effect on hMSC
proliferation and apoptosis after 72 h. This might directly result
from the interaction of 1,25D3 with its nuclear receptor nVDR
and the modulation of gene transcription. Otherwise secondary
effects could also be involved since 1,25D3 responsive genes might
regulate downstream effects. The effect on hMSC however is
different with respect to lineage commitment from e.g. that on
promyelocytes where 1,25D3 induces monocytic differentiation
together with inhibition of proliferation [20].
Numerous in vitro and in vivo studies have demonstrated that
1,25D3 inhibits proliferation of a wide range of cell types. In
smooth muscle cells 1,25D3 inhibits endothelin-induced prolifer-
ation [21–22] and Gonzalez-Pardo et al. [23] mentioned the
antiproliferative effects of 1,25D3 and the 1,25D3-analog TX527
on the growth of endothelial cells in vitro and in vivo. Our results
demonstrate the ability of 1,25D3 to inhibit proliferation rate in
hMSC compared to control cells. Human MSC grown under
permanent 1,25D3 treatment for up to six passages showed lower
CPDs compared to control cells and needed significantly more
days until they reached subconfluence, suggesting that vitamin D
signaling leads to a deceleration of proliferative processes,
accompanied by changes of cell morphology and a delay of
replicative senescence.
This could be confirmed by staining and quantification of ß-
galactosidase, an accepted marker for cellular senescence [24], in
1,25D3 treated hMSC compared to control cells. The number of
positive cells from P3 in three donors after staining for senescence-
associated ß-galactosidase was compared. The amount of ß-
galactosidase staining in 1,25D3 stimulated cells was significantly
lower compared to control hMSC. Although the determination of
ROS accumulation in 1,25D3 supplemented cells was significantly
enhanced compared to control cells (P3) 1,25D3 stimulation had
no impact on the induction of senescence in hMSC.
Although 1,25D3 is not capable of inducing robust commitment
and differentiation towards the chondrogenic, adipogenic and
osteogenic pathway, the stimulatory effect in the gut on calcium
and phosphate absorption is generally well accepted as a pro-
osteogenic and pro-mineralization effector. We determined the
multilineage capacity of 1,25D3 pretreated cells compared to
untreated control hMSC. There was no difference with respect to
their capacity to differentiate towards one of these pathways.
Moreover, there was even a tendency, although not significant,
towards enhanced chondrogenic and adipogenic differentiation. It
has been reported earlier that 1,25D3 stimulates chondrogenic
differentiation via the membrane-associated MARRS-receptor by
modulating IGF-1 production, which would be in line with our
results [25]. We conclude from these results that long-term 1,25D3
treatment in vitro did not per se induce chondrogenic, adipogenic
or osteogenic commitment and that hMSC maintain their
multipotency even after long-term stimulation with 1,25D3.
The effect of reduced proliferation and changes in cell
morphology raised the question regarding the biology of the
resulting population. To find evidence for quiescence we analyzed
the expression of known quiescence markers [26] as FOXO
mRNAs and also NANOG, TxNIP and TP53. The forkhead box O
(FOXO) proteins are activated in response to oxidative stress and
up-regulate genes involved in ROS detoxification and cell-cycle
arrest [27–28]. In five donors permanent 1,25D3 treatment leads
to a modest up-regulation of FOXO1a, FOXO3a and FOXO4.
Pierantozzi [29] could show that in hMSC Nanog homeobox
(NANOG) expression is associated with quiescence and our data
demonstrate a weak induction of NANOG expression in 1,25D3
stimulated cells in all donors. Furthermore the Thioredoxin
interacting protein (TxNIP), a regulator of hematopoietic stem cell
(HSC) quiescence under stress conditions [30], was induced in
1,25D3 treated cells. Finally also the tumor protein TP53 (P53),
which has an important role in the cellular response to DNA
damage and plays also a critical role in regulating HSC [31], is up-
regulated by 1,25D3. In summary we see a trend toward an
enhanced expression of genes associated with cellular quiescence.
This interpretation may also be fostered by the fact that 1,25D3
treatment attenuates cumulative population doublings without
inducing senescence.
To follow up the impact of permanent 1,25D3 stimulation in
hMSC we also analyzed the expression of selected genes associated
with senescence. This analysis of senescence-associated genes like
the cyclin-dependent kinase inhibitors 2B (P15), 2A (P16), 1A (P21)
and the proteasome 26S subunit, non-ATPase, 9 (P27), which
regulate the cell cycle of eukaryotic cells [32] surprisingly revealed
a significant reduction of P16 expression in permanently 1,25D3
stimulated cells. The senescence associated genes P15, P21 and
P27 were not significantly affected in comparison to unstimulated
controls. Furthermore also the pregnancy specific beta-glycopro-
teins (PSG1, PSG5), which are known to be markedly up-regulated
during replicative senescence [33] were not induced by 1,25D3.
Hence we have no evidence for an enhanced expression of
senescence-associated genes in 1,25D3 stimulated MSC, but
substantial evidence for the opposite effect.
In conclusion our data suggest that 1,25D3 does not induce
premature aging phenomena or cellular senescence in hMSC. Our
data are very much in line with the recently published phenotype
of premature aging in VDR
2/2 mice. Besides the fact that vitamin
D3 supplementation have been given to humans for at least 40
years without significant health problems our results are especially
reassuring since is established as a basic therapy in osteoporosis
prevention and treatment and is presently being discussed as a
means of cancer prevention [34]. The preponderance of evidence
from all readouts indicates that 1,25D3 does not promote aging in
this important cell population for mesenchymal tissue regeneration
but in contrast delays senescence development.
Materials and Methods
Chemicals
Chemicals were obtained from AppliChem GmbH (Darmstadt,
Germany), Applied Biosystems Deutschland GmbH (Darmstadt,
Germany), Invitrogen GmbH (Karlsruhe, Germany), Carl Roth
GmbH (Karlsruhe, Germany), R&D Systems GmbH (Wiesbaden,
Germany), Sigma-Aldrich GmbH (Schnelldorf, Germany) and GE
Healthcare Europe GmbH (Freiburg, Germany) in p. A. quality.
1,25D3 was obtained from Sigma-Aldrich GmbH (Schnelldorf,
Germany).
All experiments were performed using 1,25D3 in a concentra-
tion of 100 nM.
Isolation and culture of hMSC
Media for cell culture and fetal bovine serum were purchased
from PAA Laboratories GmbH (Linz, Austria).
Primary hMSC were isolated from femoral heads due to hip
replacement therapies from 11 different donors and cultured as
described [35–36]. Cells were plated for stimulation experiments
in P1 with or without 100 nM 1,25D3 at a density of 5000 cells
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2 and were cultivated until 80%–90% confluence at 37uCi n
5% CO2 in expansion medium (DMEM Ham’s F12 supplemented
with 10% FCS, 1 U/ml penicillin, 100 mg/ml streptomycin and
50 mg/ml ascorbate). Experiments were performed upon approval
by the Local Ethics Committee of the University of Wu ¨rzburg and
informed consent from each patient.
Isolation of RNA and RT-PCR
Total RNA was isolated using the NucleoSpinH RNAII kit
(Macherey-Nagel GmbH, Du ¨ren, Germany) according to the
manufacturer’s instructions. RNA was obtained from hMSC
cultivated for 24 h with 100 nM 1,25D3.
Two micrograms of total RNA were reverse-transcribed with
MMLV reverse transcriptase (Promega GmbH, Mannheim,
Germany) in a volume of 25 ml. For amplification of selected
genes 1 ml of cDNA was used as a template in a volume of 50 ml.
The mixture contained 106 Reaction Buffer, 20 mM each of
four dNTPs, 25 pmol each of primer and 1.25 U of Taq DNA
Polymerase (Peqlab GmbH, Erlangen, Germany). RT-PCR
conditions were as follows: 30 sec at 94 C, 30 sec at annealing
temperature, 30 sec at 72 C. The used primer-sequences,
annealing temperatures, MgCl2 concentrations, and the size of
the PCR products are listed in Table 1. Transcript amounts were
evaluated by gel electrophoresis and quantified by densitometry
analysis as described previously [37] using the LTF Bio 1D
software (LTF, Wasserburg, Germany). Values were obtained
from three to five independent experiments and were normalized
to EF1a transcripts serving as a reference. Afterwards mRNA
amounts of analyzed genes were normalized on mRNA
quantities of corresponding control. Then for each donor the
Fold Change was calculated by comparing the expression of
1,25D3 treated cells with control cells. The results are shown as
mean+SEM.
VDR immunocytochemistry
Human MSC were grown on coverslips in sixwell-plates for
three days and then stimulated with 100 nM 1,25D3 for 24 h.
Afterwards cells were washed thrice with PBS (pH 7.2), fixed with
icecold MetOH (5 min), dried and stored at 280 C until staining.
Before and after permeabilization with PBS 20.05% Tween-20,
cells were washed thrice with PBS, and then blocked with 3% BSA
in PBS. The coverslips were incubated with the primary antibody
VDR (C-20), 1:100, (sc-1008, Santa Cruz Biotechnology, Inc.,
Heidelberg, Germany) for 16 h at 4uC and a phycoerythrin-
labeled secondary antibody, NorthernLights Anti-rabbit IgG-
NL557, 1:400, (NL004, R&D Systems GmbH, Wiesbaden-
Nordenstadt, Germany) for 2 h at RT. Finally the coverslips were
applied to a drop of Vectashield with DAPI (LINARIS GmbH,
Wertheim, Germany) on slides and observed under a fluorescence
microscope (Axioskop2, filters 1 and 20, Carl Zeiss MicroImaging
GmbH, Go ¨ttingen, Germany). Pictures were taken from three
independent donors, one representative experiment is shown.
Immunophenotyping of 1,25D3 treated hMSC: Flow
cytometry
Human MSC, cultivated with or without 1,25D3 over 3
passages, were trypsinized, washed and resuspended in PBS plus
1% BSA after P1 and P3. The cells were then labeled with
fluorescein isothiocyanate (FITC)- and phycoerythrin (PE)-conju-
gated monoclonal antibodies. The antibodies used were: CD105-
PE, CD90-PE, CD73-PE (mesenchymal markers), HLA-DR-
FITC (AbD Serotec, Du ¨sseldorf, Germany) CD34-FITC, CD45-
FITC (hematopoietic markers) (BD Biosciences, Heidelberg,
Germany). Mouse isotype antibodies served as controls (BD
Biosciences, Heidelberg, Germany). Then hMSC were washed
twice with PBS plus 1% BSA. For fluorescence activated cell
sorting analysis (FACS) labeled cells were resuspended in PBS plus
1% BSA at a concentration of 8610
5 cells/ml. Flow cytometry
analysis (10000 events) was performed using a BD LSR II (Becton
Dickinson, Heidelberg, Germany). Figures were generated using
FlowJo software. Analyses were performed by using three
independent donors.
Colony Forming Unit (CFU) Assay
1,25D3 treated hMSC and control hMSC at P1 and P3
respectively were cultured in Petri dishes. The medium was totally
renewed every 3–4 days. Fifteen days after standardized seeding at
800 cells per Petri dish (14 cells per cm
2), cells were washed 2 times
with PBS, fixed with methanol, and stained with 0.5% Crystal
Violet. Cell clusters of more than 25 cells were counted as CFU
originating from one clonal cell. The CFUs were scored using
AxioVision Rel. 4.6 (Carl Zeiss MicroImaging GmbH, Go ¨ttingen,
Germany). Experiments were performed in three to five
independent donors.
Cell proliferation and apoptosis assay
For determination of 1,25D3 short-term effects on proliferation
and apoptosis, hMSC (P1 or 2, respectively) were seeded on 96
well plates (1000 cells/well). 24 h after seeding hMSC were
stimulated with 100 nM 1,25D3 for 24, 48 and 72 h. Proliferation
and apoptosis rates of treated hMSC compared to non-treated
hMSC were quantified by Caspase-GloH 3/7 Assay and CellTiter-
GloH 3/7 Luminescent Cell Viability Assay (both Promega
GmbH, Mannheim, Germany) according to the manufacturer’s
instructions. Luminescence was measured with an Orion II
Luminometer (Berthold Detection Systems, Pforzheim, Germany).
Proliferation and apoptosis experiments were performed by using
hMSC of 3 human donors. Averages were calculated from 3
different measuring points and 3 independent hMSC preparations.
Growth rate analysis
Passage 0 hMSC were trypsinized and reseeded in culture
media with or without 100 nM 1,25D3 at a density of 5000 cells
per cm
2. These hMSC were allowed to grow until they reached
80%–90% confluence and then passaged at the same cell density
onwards up to P6. As the cell number of hMSC could be
determined for the first time at P1, the cumulative population
doubling (CPD) was first determined for P2. CPDs were calculated
as described previously [38–39].
Retransformation of 1,25D3 treated hMSC
After three passages of 1,25D3 supplementation, half of these
hMSC were cultivated 1,25D3-deprived, whereas the other half
was still stimulated. 200 cells per cm
2 were seeded and after a
growth period of two weeks the cell number of 1,25D3 treated and
1,25D3 untreated hMSC was determined.
Senescence-associated ß-galactosidase staining and
determination of ß-galactosidase positive cells
For detection of senescent cells senescence-associated ß-
galactosidase staining (counterstain: Nuclear fast red, Merck
KGaA, Darmstadt; Germany) was performed as described [24]
Cells were observed under the microscope for positive blue stained
cytoplasm. Each time five pictures of ß-galactosidase staining of
three independent donors were quantified using the AutMess tool
of AxioVision Rel. 4.6 software.
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In first-passage and third-passage hMSC cultivated with or
without 1,25D3, the accumulation of reactive oxygen species
(ROS) was determined using 2979-dichlorofluorescin diacetate
(H2DCF-DA). Intracellular ROS, e.g. hydrogen peroxide, oxidize
nonfluorescent H2DCF-DA to fluorescent dichlorofluorescin
(DCF) [40–41]. Cells were incubated with 30 mMH 2DCF-DA
for 45 min, trypsinized, and washed three times with PBS plus 1%
BSA. The rate of oxidation was analyzed (3610
5 cells/sample) by
flow cytometry using a BD LSR I (Becton Dickinson, Heidelberg,
Germany) after incubation for 10 min on ice with 1 mg/ml
propidium iodide, as described by Schupp et al. [42]. The
obtained data were evaluated with the CellQuest Pro software, by
defining a region within the DCF-propidium iodide dot blot
containing 2610
3 propidium iodide-negative cells. The mean
value of this population was determined and used for the statistical
analysis. Data were obtained from three independent experiments.
In Vitro Differentiation
Human MSC cultivated with and without 100 nM 1,25D3 for 3
passages were used for differentiation experiments. Differentiation
experiments were started in P3 when cells had reached confluence.
Human MSC were incubated in expansion medium (negative
control) or in cell differentiation medium.
Table 1. Primers used for RT-PCR experiments.
Primer Sequence 59R39 Product size (bp) Cycles (n) Tm (6C) MgCl2 (mM)
EF-1-a for AGGTGATTATCCTGAACCATCC 233 30 54 1.5
EF-1-a rev AAAGGTGGATAGTCTGACTGTTG 233 30 54 1.5
P16 for CTTCCTGGACACGCTGGT 138 35 55 2.0
P16 rev GCATGGTTACTGCCTCTGGT 138 35 55 2.0
24OHASE for TATGAGGCTTACGCCGAGTG 446 40 62 1.5
24OHASE rev CCGCTTCCCTGAGTTGGATG 446 40 62 1.5
OP for ACCCTTCCAAGTAAGTCCAA 400 40 58 2.5
OP rev GTGATGTCCTCGTCTGTAGC 400 40 58 2.5
OC for ATGAGAGCCCTCACACTCCTC 293 35 60 2.5
OC rev GCCGTAGAAGCGCCGATAGGC 293 35 60 2.5
PSG1 for TGAAGTCAGCCTTGGTTTGG 240 35 55 2.5
PSG1 rev TTTCCCTCTATGGGCATCTC 240 35 55 2.5
PSG5 for TACAAAGGACAACTGATGGACC 540 30 57 2.5
PSG5 rev CTGGGGAGGTCTGGACCAT 540 30 57 2.5
FOXO1a for GACGCCGTGCTACTCGTT 458 37 55 3
FOXO1a rev CGGTTCATACCCGAGGTG 458 37 55 3
FOXO3a for AACCCAGGGCGCTCTTGGTG 281 38 62 3
FOXO3a rev ATGAGTTCACTACGGATAATGGA 281 38 62 3
FOXO4 for CCCTCTCAGGAGCCATCA 530 37 55 3
FOXO4 rev ACCTGGTCCGTAGGGGAG 530 37 55 3
P21 for CGACTGTGATGCGCTAATGG 482 28 55 1
P21 rev ACAAACTGAGACTAAGGCAGAAGA 482 28 55 1
NANOG for TTCCTTCCTCCATGGATCTG 448 35 51 2
NANOG rev ATTGTTCCAGGTCTGGTTGC 448 35 51 2
TxNIP for CCTGGTAATTGGCAGCAGATC 199 28 51 2
TxNIP rev CTTGAGACCATCCATGTCA 199 28 51 2
TP53 for CCTCCTCAGCATCTTATCCG 259 28 55 1
TP53 rev GCACAAACACGCACCTCAAA 259 28 55 1
P15 for CGTTAAGTTTACGGCCAACG 302 43 58 1
P15 rev GGTAGAGTGGCAGGGTCT 302 43 58 1
P16 for GGTGCGGGCGCTGCTGGA 210 43 46 1
P16 rev AGCACCACCAGCGTGTCC 210 43 46 1
P21 for GGAAGACCATGTGGACCTGT 403 27 58 1
P21 rev ATGCCCAGCACTCTTAGGAA 403 27 58 1
P27 for AGTTCGGCTCTGTGAACACC 336 27 58 1
P27 rev CCACAGTACTGCCACCACAC 336 27 58 1
Primer sequences, fragment lengths and PCR conditions including number of cycles, annealing temperature and magnesium supplementation.
doi:10.1371/journal.pone.0029959.t001
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differentiation hMSC were cultured as high-density pellet
cultures. Therefore 2.5610
5 cells were resuspended in
chondrogenic differentiation medium (DMEM high glucose
supplemented with 50 mg/ml ascorbate-2-phosphate, 100 nM
dexamethasone, 100 mg/ml pyruvate, 40 mg/ml proline, 1%
ITS+1, 1 U/ml penicillin, 100 mg/ml streptomycin and 10 ng/
ml TGF-b-1, with and without the addition of 100 nM 1,25D3),
centrifuged in a 15 ml polypropylene tube (Greiner Bio-One
GmbH, Frickenhausen, Germany) at 250 g to form a pellet, and
cultured for three weeks as described previously [35]. Pellets
cultured in chondrogenic differentiation medium without the
addition of TGF-b-1 served as negative controls. Chondrogenic
high-density pellet cultures were fixed in 4% paraformaldehyde,
dehydrated through a graded ethanol series and embedded in
paraffin. Sections of 4 mm were stained with 1% Alcian Blue
(pH 1.0) for sulfated proteoglycans and counterstained with
Nuclear Fast Red. Cells cultured in expansion medium served as
negative control.
Adipogenic Differentiation. For adipogenic differentiation
hMSC were seeded at a density of 2.1610
4 cells per cm
2,
cultivated until confluence and incubated in adipogenic
differentiation medium consisting of DMEM high glucose, 10%
FCS, 1 U/ml penicillin, 100 mg/ml streptomycin, 1 mM
dexamethasone, 0.5 mM 3-isobutyl-1-methylxanthine (IBMX),
1 mg/ml insulin and 100 mM indomethacin. At day 14
intracellular lipid vesicles of adipogenic monolayer cultures were
stained with Oil Red O solution (Merck, Darmstadt, Germany)
[43]. During the adipogenic differentiation process, no 1,25D3
was applied. Cells cultured in expansion expansion medium served
as negative control.
Osteogenic Differentiation. For osteogenic differentiation
cells were seeded at a density of 2.1610
4 cells per cm
2 and grown
until confluence. Osteogenic differentiation of confluent
monolayer cultures was then induced with osteogenic
differentiation medium (DMEM high glucose supplemented with
10% FCS, 50 mg/ml ascorbate, 10 mM b-glycerophosphate,
1 U/ml penicillin, 100 mg/ml streptomycin and 100 nM
dexamethasone) for four weeks. During the osteogenic
differentiation process, no 1,25D3 was applied. Cells cultured in
expansion expansion medium served as negative control. The
mineralized extracellular matrix was determined by staining for
calcium hydrogen phosphate using Alizarin Red S (Chroma-
Gesellschaft Scnmid & Co., Stuttgart, Germany) as described
previously [44]. Cytoplasmic ALP was stained using the Alkaline
Phosphatase, Leukocyte Kit 86-C (Sigma Aldrich GmbH,
Munich, Germany) according to the manufacturer’s instructions.
Statistics
The results are expressed as means+standard error (SEM). For
comparison between two groups the student’s t-test and the Mann-
Whitney U test were performed as indicated.
Supporting Information
Figure S1 Immunophenotyping of 1,25D3 treated hMSC
compared to untreated hMSC. 1,25D3 treated hMSC and
untreated cells at passage 1 (A) and 3 (B) were analyzed with flow
cytometry to detect the cell surface marker expression. Results are
shown for one representative donor. Yellow peaks represent the
specific antibody staining of control cells, blue peaks represent the
specific antibody staining of 1,25D3 treated hMSC, and red peaks
represent the isotype control antibody staining of 1,25D3 cultured
cells (right panels). Histogram overlays show 1,25D3 treated
hMSC and control cells gated for CD73, CD90 and CD105
positivity. CD73, CD90 and CD105 expression of 1,25D3 treated
cells and untreated hMSC was between 88.9% and 98.7%. This
was consistent over three separate experiments using hMSC from
three donors (control=1,25D3 untreated cells; 1,25D3=1,25D3
stimulated hMSC; IgG=isotype control).
(TIF)
Figure S2 Number of CFUs of 1,25D3 treated hMSC.
After passage 1 and 3 the effect of 1,25D3 treatment on CFU
number was evaluated in hMSC and compared to untreated
hMSC. No significant difference was obtained in CFU number
between 1,25D3 treated cells (gray bars) and control hMSC (black
bars) at P1 and also at P3. Data show mean+SEM of three (P3) or
five (P1) independent experiments, respectively.
(TIF)
Figure S3 Retransformation of 1,25D3 stimulated
hMSC. A The 1,25D3 induced morphological changes are not
completely reversible when 1,25D3 treated hMSC are again
cultured in normal medium. Some cells retrained their 1,25D3
induced enlarged volume (r.c.=retransformed cells;
1,25D3=1,25D3 treated hMSC). The results are shown for one
representative donor and observations were consistent over 3
independent experiments using hMSC from three donors. Scale
bar=50 mm. B The cell number of 1,25D3 treated and
retransformed cells was determined. Data show mean+SEM of
three independent experiments using cells from three donors.
C The cell number of 1,25D3 treated and retransformed cells was
determined. Therefore three donors were analyzed. Retrans-
formed hMSC displayed an obvious higher cell number compared
to 1,25D3 treated cells
(TIF)
Figure S4 Osteogenic differentiation capacity of 1,25D3
treated hMSC. A Staining for ALP after osteogenic differenti-
ation for 14 days (upper row) and for 28 days (lower row).
Staining for cytoplasmic ALP was performed for undifferentiated
hMSC (n.d.) as well as for hMSC pretreated with and without
1,25D3 (C=differentiated control; +1,25D3=differentiated
1,25D3 pretreated cells). The figure is representative of three
independent experiments. Scale bar=50 mm. B Quantification of
ALP staining after 1,25D3 pretreatment over 3 passages and
1,25D3 untreated hMSC over 3 passages as a result of two or four
weeks of osteogenic differentiation. The Fold Change was
calculated by comparing the induction of differentiation of
1,25D3 pretreated cells with control cells. After two weeks under
osteogenic conditions, 1,25D3 pretreated hMSC showed a slightly
enhanced ALP staining compared to untreated cells, and after
four weeks under osteogenic conditions, 1,25D3 pretreated
hMSC revealed significant reduced ALP staining compared to
untreated hMSC (*; p,0.05, student’s t-test). The results are
shown as means of three independent experiments+SEM using
different preparations of hMSC. Each time 6 pictures of ALP
staining were analyzed using the AutMess tool of AxioVision Rel.
4.6 software.
(TIF)
Figure S5 Flow cytometric analysis of 1,25D3-induced
ROS formation in hMSC after P1 and P3. Oxidative stress
in cells cultured for one passage (A) and for three passages (B) with
(gray bar) and without (black bar) 1,25D3. The results are shown
as mean+SEM of three independent experiments, each normal-
ized to its control and performed in triplicates. Cells from four
different donors were used (*, p,0.05, Mann-Whitney U test).
(TIF)
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